-Amyloid(1–42) CSF immunoassay in the CREAD (BN29552) study of crenezumab in prodromal-to-mild AD
Grimmer, T., Rabe, C., Navarro, M., Clayton, D., Manuilova, E., Peters, O., Eichenlaub, U., Smith, J., Ostrowitzki, S., Honigberg, L., Bittner, T.Volume:
130
Language:
english
Journal:
Clinical Neurophysiology
DOI:
10.1016/j.clinph.2019.04.662
Date:
August, 2019
File:
PDF, 48 KB
english, 2019